ARVINAS, INC. (ARVN) Form 8-K — Aug 4, 2026

$ARVNForm 8-KItems 2.02, 9.01Filed Aug 4, 2026, 7:02 AM ET0001628280-26-052139Original filing

Arvinas reported second quarter 2026 financial results highlighted by the first-ever FDA approval of a PROTAC drug, VEPPANU, for ER+/HER2- advanced or metastatic breast cancer. The company also entered into an exclusive license agreement with Rigel Pharmaceuticals for the global development and commercialization rights to VEPPANU. Driven by the approval and licensing milestone, revenue surged to $249.7 million compared to $22.4 million in the prior year quarter, resulting in net income of $169.4 million or $2.61 per share. The company ended the quarter with cash, cash equivalents, and marketable securities of $567.9 million, which it expects will fund operations into the second half of 2028.

Key figures

Eps: $2.61
Revenue: $249.7 million
Net Income: $169.4 million
Cash Position: $567.9 million
Cash burn 6mo: $117.5 million
Rigel milestone: $35.0 million

Price after filing

1 day: -2.9%7 days: +8.3%30 days: +15.5%

Close on the filing date to close N calendar days later (from $8.30). Historical, not a forecast.

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.